SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 10:54:13 2024-06-03 am EDT | ||
| 3.39 EUR | -3.42% |
|
| 1 month | +9.01% | ||
| 3 months | +31.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 3.39 | -3.42% |
| 24-05-31 | 3.51 | -1.40% |
| 24-05-30 | 3.56 | -0.56% |
| 24-05-29 | 3.58 | +0.85% |
| 24-05-28 | 3.55 | +2.60% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 10:54 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU0WND |
| ISIN | DE000VU0WND9 |
| Date issued | 2022-12-15 |
| Strike | 79.13 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.61 € |
|---|---|
| Lowest since issue | 0.5 € |
| Spread | 0.01 € |
| Spread % | 0.29% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat
